Previous
Previous

Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma

Next
Next

Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor